US FDA will not convene expert panel for Capricor Therapeutics’ DMD cell therapy
By Thomson ReutersJun 24, 2025 | 9:52 AM
(Reuters) -Capricor Therapeutics said on Tuesday the U.S. Food and Drug Administration will not convene its panel of outside experts before deciding on the company’s cell therapy for a heart condition associated with Duchenne muscular dystrophy.
Comments